Over 18 billion yuan of market, a large number of domestic pharmaceutical companies are actively layout!

Recently, there have been reports that the FDA has approved Auvelity, a new drug developed by Axsome, for the treatment of Major Depressive Disorder (MDD)
in adults.
It is understood that Auvelity has been certified as a breakthrough therapy by the FDA and has obtained priority review qualifications, and is the first oral antidepressant with a new mechanism approved in more than 60 years, and it is also an oral therapy
that can quickly start within a week and significantly improve depressive symptoms.
Axsome expects to make the first U.
S.
launch of Auvelity in the fourth quarter of
this year.
Analysts believe that with the advantages of fast comprehensive effect, strong effect, new mechanism, no weight gain, etc.
, Auvelity market sales prospects can be expected
.
The main reason for this conclusion is that the antidepressant market is growing as the problem of depression becomes more serious and the attention increases
.
Depression is a common psychiatric disorder, and about 280 million people in the world suffer from depression
.
At present, modern medical treatment for depression mainly includes three types
: drug therapy, psychological therapy, and physical therapy.
Among them, drug therapy is the main means
of treatment for depression.
In recent years, the size of the domestic and foreign antidepressant market has been continuously rising
.
Especially in China, according to data, in 2021, the sales of terminal antidepressants in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) have exceeded 8.
7 billion yuan.

According to the consulting agency Sullivan, the size of China's antidepressant market will reach 18.
41 billion yuan
in 2022.
With the increase in the number of patients and the continuous expansion of the market size, a large number of pharmaceutical companies have begun to accelerate their layout in this field and begin to usher in results
.
In addition to the above-mentioned Axsome, according to incomplete statistics, there are currently 17 Class 1 innovative drugs in China that are in the approved clinical and above stages, involving many enterprises
such as Luye Pharmaceutical, Huahai Pharmaceutical, CSPC Pharmaceutical Group, and Haosen Pharmaceutical.
Among them, Yiling Pharmaceutical, an exclusive patented new drug for the treatment of depression and anxiety disorders, Antidepressant Capsules, was approved for marketing
at the end of 2021.
Luye Pharmaceutical's Anshufaxine hydrochloride extended-release tablets have also submitted a marketing application, which is a class 1 chemical new drug independently developed by Luye Pharmaceutical Group, which is suitable for major depressive disorder
.
In addition to innovative drugs, in terms of generic drugs, domestic pharmaceutical companies are also very prominent
.
It is reported that on September 21, Fuyuan Pharmaceutical issued an announcement that the company received the "Drug Registration Certificate" issued by the State Food and Drug Administration for Paroxetine hydrochloride enteric-coated extended-release tablets (specifications: according to C19H20FNO3 (1) 12.
5mg, (2) 25mg) and approved the production of
the drug.
This time to obtain the "Drug Registration Certificate" is deemed to have passed the consistency evaluation
.
Paroxetine hydrochloride enteric-coated extended-release tablets were originally developed as GSK and were released
in the United States on February 16, 1999.
According to GlaxoSmithKline's 2021 annual report, global sales of the product are $152 million
.
On September 6, the website of the State Food and Drug Administration showed that Agomelatine tablets of Haosen Pharmaceutical passed the consistency evaluation and became the first in China
.
Agomelatine is a new type of antidepressant, with sales of terminals in public medical institutions in China approaching 600 million yuan
in 2021.
Hausen's products were approved for listing in 2014, which is the first imitation in China
.
In August, Poinsettia also announced that its wholly-owned subsidiary Guangzhou Poinsettia Pharmaceutical's Wenlafaxine hydrochloride extended-release capsules (specification: 75mg) were approved for marketing, which was deemed to have passed the consistency evaluation of
generic drugs.
This product is used to treat depression (including depression with anxiety) and generalized anxiety disorders, and is the first-line treatment recommended by the guidelines for the diagnosis and treatment of depression and generalized anxiety disorder in many countries
.
Overall, the antidepressant market has a huge space and is currently attracting more and more pharmaceutical companies to enter
.
However, it should be noted that the domestic antidepressant market has been occupied
by foreign pharmaceutical companies for many years due to the early entry time of the original research drugs.
Therefore, although at present, with the expiration of the original research drug patent and the implementation of policies such as collection and medical insurance negotiation, the layout of domestic enterprises in the antidepressant market has gradually increased, but it is still slightly insufficient
in innovation and product types.
Industry analysts believe that only pharmaceutical companies with good innovation capabilities in the future can help domestic antidepressants accelerate import substitution, and push internationally competitive antidepressants overseas to participate in global market competition
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.